Azoles
Medchemexpress LLC GAL-02-221 | 2409538-70-9 | 99.9% | 1016.67 | 10 MG
GAL-02-221 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. It can potently degrade BRD4 in HER2 positive and negative breast cancer cell lines.
- Potently degrades BRD4
- Degrades BRD4 in HER2 positive and negative breast cancer cell lines
- Connected by ligands for von Hippel-Lindau and BRD4
- Shows antiproliferative activity against human 22Rv1, L02, MCF7, and MDA-MB-231 cells
Medchemexpress LLC 1,3-oxazolidine-2-thione | 5840-81-3 | MFCD00125763 | 99.4% | 103.14 g·mol⁻¹ | C3H5NOS | 25 MG
1,3-Oxazolidine-2-thione (CAS 5840-81-3) is a small-molecule oxazolidinethione used as a research reagent. It is a low-molecular-weight compound (C3H5NOS, 103.14 g·mol⁻¹) supplied at high purity for laboratory studies. It has been reported to increase thyroid size and to markedly depress hepatic trimethylamine oxidase activity in avian models. For research use only.
- High purity suitable for analytical and biological research.
- Well-characterized molecular properties for reproducible experiments.
- Available in small pack sizes for screening and mechanistic studies.
- Reported biological activity relevant to endocrine and hepatic research.
- Intended for research use only; not for human or veterinary use.
eMolecules 585-48-8 | 2,6-Di-tert-butylpyridine | Oakwood Chemicals | MFCD00006306 | 191.318 | C13H21N | 97.000 | CC(C)(C)c1cccc(n1)C(C)(C)C | 25g | 480163151
2,6-Di-tert-butylpyridine | Oakwood Chemicals | 585-48-8 | MFCD00006306 | 191.318 | C13H21N | 97.000 | CC(C)(C)c1cccc(n1)C(C)(C)C | 25g | 480163151
eMolecules 38862-24-7 | 2,5-Dioxopyrrolidin-1-yl acrylate | Ambeed | MFCD00078261 | 169.136 | C7H7NO4 | 97.000 | C=CC(=O)ON1C(=O)CCC1=O | 5g | 552526336
2,5-Dioxopyrrolidin-1-yl acrylate | Ambeed | 38862-24-7 | MFCD00078261 | 169.136 | C7H7NO4 | 97.000 | C=CC(=O)ON1C(=O)CCC1=O | 5g | 552526336
Selleck Chemical LLC GGTI 298 TFA salt
GGTI 298 is a geranylgeranyltransferase I inhibitor with ability to arrest human tumor cells in the G1 phase of the cell cycle and induce apoptosis
(C)OCCN | 5g | 303351988](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000165194.jpg-250.jpg)
eMolecules 101711-55-1 | 2-(tert-Butyldimethylsilyloxy)ethanamine | Combi-Blocks | MFCD18206132 | 175.347 | C8H21NOSi | 95.000 | CC(C)(C)[Si](C)(C)OCCN | 5g | 303351988
2-(tert-Butyldimethylsilyloxy)ethanamine | Combi-Blocks | 101711-55-1 | MFCD18206132 | 175.347 | C8H21NOSi | 95.000 | CC(C)(C)[Si](C)(C)OCCN | 5g | 303351988
Sigma Aldrich Fine Chemicals Biosciences 2,4,5-Trimethylthiazole >=98%, FG | 13623-11-5 | MFCD00005332 |
2,4,5-Trimethylthiazole >=98%, FG | Purity: >=98% | Mol Wt: 127.21 | 13623-11-5 | MFCD00005332 |
![Apexbio Technology LLC Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] 10mg](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000095213.png-250.jpg)
Apexbio Technology LLC Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] 10mg
Cytochrome P450 CYP1B1 190-198 is a tumor-associated antigen peptide derived from CYP1B1 It is designed to induce HLA-A2-restricted T-cell responses against the CYP1B1(190-198) epitope thereby promoting tumor-specific cytotoxic immune responses Cytochrome P450 CYP1B1 190-198 exerts its biological activity primarily through antigen-specific activation of CD8 T cells In HLA-A2 transgenic mouse models this peptide delivered via plasmid DNA and poly(lactide-co-glycolide) microparticles demonstrates the ability to elicit CYP1B1 peptide-specific T-cell immunity Based on these pharmacological properties Cytochrome P450 CYP1B1 190-198 holds research potential in cancer immunotherapy and studies of tumor-specific cytotoxic T-cell responses